This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

James H. Stein, MD; Robert S. Rosenson, MD

Arch Intern Med. 1997;157(11):1170-1176.

Abstract
Lipoprotein Lp(a) excess has been identified as a powerful predictor of premature atherosclerotic vascular disease in several large, prospective studies. Lipoprotein Lp(a) levels modulate the risk of coronary heart disease in patients with hypercholesterolemia, and lipoprotein Lp(a) excess is commonly detected in men and women with premature coronary atherosclerosis. Lipoprotein Lp(a) contributes to atherothrombotic risk by multiple mechanisms that include impaired fibrinolysis, increased cholesterol deposition in the arterial wall, and enhanced oxidation of low density lipoprotein cholesterol. Although low density lipoprotein cholesterol reduction is the primary intervention in patients with lipoprotein Lp(a) excess, specific therapy to lower lipoprotein Lp(a) may be indicated for patients with premature coronary atherosclerosis, a strong family history of premature atherosclerosis, or refractory hypercholesterolemia. In consideration of the high prevalence of lipoprotein Lp(a) excess in patients with premature coronary heart disease and the intricate role of lipoprotein Lp(a) in atherothrombosis, this review provides an evidence-based approach to the screening and treatment of patients with lipoprotein Lp(a) excess.

Arch Intern Med. 1997;157:1170-1176

Author Affiliations
From the Section of Cardiology and the Preventive Cardiology Program, the University of Wisconsin Medical School, Madison (Dr Stein), and the Preventive Cardiology Center, Rush-Presbyterian-St Luke's Medical Center, Chicago, Ill (Dr Rosenson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Portal and Mesenteric Vein Thromboses in a Patient With Prothrombin G20210 Mutation, Elevated Lipoprotein (a), and High Factor VIII
Jana et al.
CLIN APPL THROMB HEMOST 2008;14:481-485.
ABSTRACT  

High Levels of Inflammatory Biomarkers Are Associated with Increased Allele-Specific Apolipoprotein(a) Levels in African-Americans
Anuurad et al.
J. Clin. Endocrinol. Metab. 2008;93:1482-1488.
ABSTRACT | FULL TEXT  

Effects of Testosterone Therapy on Cardiovascular Risk Markers in Androgen-Deficient Women with Hypopituitarism
Miller et al.
J. Clin. Endocrinol. Metab. 2007;92:2474-2479.
ABSTRACT | FULL TEXT  

ApoE genotype affects allele-specific apo[a] levels for large apo[a] sizes in African Americans: the Harlem-Basset Study
Anuurad et al.
J. Lipid Res. 2007;48:693-698.
ABSTRACT | FULL TEXT  

Apo[a] size and PNR explain African American-Caucasian differences in allele-specific apo[a] levels for small but not large apo[a]
Rubin et al.
J. Lipid Res. 2006;47:982-989.
ABSTRACT | FULL TEXT  

Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier?
Shai et al.
Eur Heart J 2005;26:1633-1639.
ABSTRACT | FULL TEXT  

Advanced Lipoprotein Testing Does Not Improve Identification of Subclinical Atherosclerosis in Young Adults: The Bogalusa Heart Study
Tzou et al.
ANN INTERN MED 2005;142:742-750.
ABSTRACT | FULL TEXT  

Lipoprotein(a): An Elusive Cardiovascular Risk Factor
Berglund and Ramakrishnan
Arterioscler. Thromb. Vasc. Bio. 2004;24:2219-2226.
ABSTRACT | FULL TEXT  

The Prevalence of Nontraditional Risk Factors for Coronary Heart Disease in Patients with Chronic Kidney Disease
Muntner et al.
ANN INTERN MED 2004;140:9-17.
ABSTRACT | FULL TEXT  

Subclinical Hypothyroidism and Lipid Abnormalities in Older Women Attending a Vascular Disease Prevention Clinic: Effect of Thyroid Replacement Therapy
Ganotakis et al.
ANGIOLOGY 2003;54:569-576.
ABSTRACT  

Androgens and Coronary Artery Disease
Wu and von Eckardstein
Endocr. Rev. 2003;24:183-217.
ABSTRACT | FULL TEXT  

Estrogen Receptors {alpha} and {beta} Have Similar Activities in Multiple Endothelial Cell Pathways
Evans et al.
Endocrinology 2002;143:3785-3795.
ABSTRACT | FULL TEXT  

Effect of Aspirin Treatment on Serum Concentrations of Lipoprotein(a) in Patients with Atherosclerotic Diseases
Akaike et al.
Clin. Chem. 2002;48:1454-1459.
ABSTRACT | FULL TEXT  

Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians
Rubin et al.
J. Lipid Res. 2002;43:234-244.
ABSTRACT | FULL TEXT  

Relation of Apo(a) Size to Carotid Atherosclerosis in an Elderly Multiethnic Population
Paultre et al.
Arterioscler. Thromb. Vasc. Bio. 2002;22:141-146.
ABSTRACT | FULL TEXT  

Vascular complications in diabetes and their prevention
Kassab et al.
Vasc Med 2001;6:249-255.
ABSTRACT  

Fluorescence-based, Nonradioactive Method for Efficient Detection of the Pentanucleotide Repeat (TTTTA)n Polymorphism in the Apolipoprotein(a) Gene
Rubin et al.
Clin. Chem. 2001;47:1758-1762.
ABSTRACT | FULL TEXT  

Lipoprotein(a) and Cognitive Performances in an Elderly White Population : Cross-Sectional and Follow-Up Data
Sarti et al.
Stroke 2001;32:1678-1683.
ABSTRACT | FULL TEXT  

Non-High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality
Cui et al.
Arch Intern Med 2001;161:1413-1419.
ABSTRACT | FULL TEXT  

Does Pioglitazone, Like Troglitazone, Increase Serum Levels of Lipoprotein(a) in Diabetic Patients?
Nagai et al.
Diabetes Care 2001;24:408-a-409.
FULL TEXT  

Determinants of human apolipoprotein [a] secretion from mouse hepatocyte cultures
Wang et al.
J. Lipid Res. 2001;42:60-69.
ABSTRACT | FULL TEXT  

High Levels of Lp(a) With a Small Apo(a) Isoform Are Associated With Coronary Artery Disease in African American and White Men
Paultre et al.
Arterioscler. Thromb. Vasc. Bio. 2000;20:2619-2624.
ABSTRACT | FULL TEXT  

Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism
von Depka et al.
Blood 2000;96:3364-3368.
ABSTRACT | FULL TEXT  

Lipoprotein (a) and stroke
Milionis et al.
J. Clin. Pathol. 2000;53:487-496.
ABSTRACT | FULL TEXT  

Estrogen and Progestin, Lipoprotein(a), and the Risk of Recurrent Coronary Heart Disease Events After Menopause
Shlipak et al.
JAMA 2000;283:1845-1852.
ABSTRACT | FULL TEXT  

Substituting Walnuts for Monounsaturated Fat Improves the Serum Lipid Profile of Hypercholesterolemic Men and Women: A Randomized Crossover Trial
Zambon et al.
ANN INTERN MED 2000;132:538-546.
ABSTRACT | FULL TEXT  

Lack of association of lipoprotein(a) levels with coronary calcium deposits in asymptomatic postmenopausal women
Nishino et al.
J Am Coll Cardiol 2000;35:314-320.
ABSTRACT | FULL TEXT  

Aspirin Reduces Apolipoprotein(a) (Apo(a)) Production in Human Hepatocytes by Suppression of Apo(a) Gene Transcription
Kagawa et al.
J. Biol. Chem. 1999;274:34111-34115.
ABSTRACT | FULL TEXT  

Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen
Harjai
ANN INTERN MED 1999;131:376-386.
ABSTRACT | FULL TEXT  

Estrogen Modulation of Apolipoprotein(a) Expression. IDENTIFICATION OF A REGULATORY ELEMENT
Boffelli et al.
J. Biol. Chem. 1999;274:15569-15574.
ABSTRACT | FULL TEXT  

Emerging Noninvasive Biochemical Measures to Predict Cardiovascular Risk
Pahor et al.
Arch Intern Med 1999;159:237-245.
ABSTRACT | FULL TEXT  

Effect of HMG-CoA Reductase Inhibitors on Coronary Artery Disease as Assessed by Electron-Beam Computed Tomography
Callister et al.
NEJM 1998;339:1972-1978.
ABSTRACT | FULL TEXT  

Evolving lipoprotein risk factors: lipoprotein(a) and oxidized low-density lipoprotein
Jialal
Clin. Chem. 1998;44:1827-1832.
ABSTRACT | FULL TEXT  

Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction
Rosenson and Tangney
JAMA 1998;279:1643-1650.
ABSTRACT | FULL TEXT  

Should We Measure Lipoprotein Lp(a)?
Wilson and Kannel
Arch Intern Med 1997;157:1161-1162.
ABSTRACT